Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo, Torino, Italy.
Breast Cancer Res. 2010;12(4):208. doi: 10.1186/bcr2617. Epub 2010 Aug 23.
Recent findings suggest the involvement of the MET oncogene, encoding the tyrosine kinase receptor for hepatocyte growth factor, in the onset and progression of basal-like breast carcinoma. The expression profiles of basal-like tumors - but not those of other breast cancer subtypes - are enriched for gene sets that are coordinately over-represented in transcriptional signatures regulated by Met. Consistently, tissue microarray analyses have revealed that Met immunoreactivity is much higher in basal-like cases of human breast cancer than in other tumor types. Finally, mouse models expressing mutationally activated forms of Met develop a high incidence of mammary tumors, some of which exhibit basal characteristics. The present review summarizes current knowledge on the role and activity of Met in basal-like breast cancer, with a special emphasis on the correlation between this tumor subtype and the cellular hierarchy of the normal mammary gland.
最近的研究结果表明,MET 癌基因(编码肝细胞生长因子的酪氨酸激酶受体)参与了基底样乳腺癌的发生和发展。基底样肿瘤的表达谱 - 而不是其他乳腺癌亚型的表达谱 - 富含协调地过度表达受 Met 调节的转录特征的基因集。一致地,组织微阵列分析表明,Met 免疫反应性在人类乳腺癌的基底样病例中比其他肿瘤类型高得多。最后,表达突变激活形式的 Met 的小鼠模型会发展出很高的乳腺肿瘤发生率,其中一些表现出基底特征。本综述总结了 Met 在基底样乳腺癌中的作用和活性的最新知识,特别强调了这种肿瘤亚型与正常乳腺的细胞层次结构之间的相关性。